Your clinical advisor said great things about the product on last month's webinar. Her quote is on the website. Her name is on the funding deck. And she still hasn't recommended the app to a single patient in her own clinic.
Those are two separate decisions. They run on two different kinds of trust.
The public yes and the private yes
The public yes costs her almost nothing. Sitting on an advisory board or giving a quote for a case study is a professional favor extended to a founder she likes, in a context where nothing goes wrong if the product underperforms. Nobody traces a bad outcome back to a webinar appearance.
The private yes is a different transaction entirely. When she puts your app in front of an actual patient, she's staking her own judgment and her relationship with that patient on it. If it goes badly, the advisory board bio doesn't cover her. Her name does, and it's the only name in the room.
Founders collect the first kind of yes and quietly assume it predicts the second. It doesn't. A clinician can believe in your mission, respect you personally, and still hold her actual patients to a completely different bar than the one she holds your pitch to.
What the private question actually asks
Ask a clinician what she needs to know before recommending a digital health tool to a real patient, and the advisory board pitch barely registers. Market opportunity and the vision slide: none of it survives contact with a 12 minute appointment. She's running a narrower, more specific set of checks instead.
Can she explain this in the 90 seconds she has left in the visit. Will it work for a 68 year old who's never opened an app on her own before. What happens if the patient stops using it after week one, and does that become a problem she has to manage or one the product quietly absorbs. And if something goes wrong, who's accountable: her, for the recommendation, or you, for the tool.
Liability sits underneath every one of those questions
A clinician who recommends your app is extending her own clinical judgment to cover it. That makes it a liability question before it's a product question, and she'll ask it of herself, quietly, long before she ever asks your sales team out loud.
This is why a glowing public quote and a real recommendation can come from the same person in the same month and mean almost nothing about each other. One has no downside attached to her name. The other has all of it.
Why the gap survives so long unnoticed
Founders rarely discover this gap exists, because the advisory relationship keeps sending positive signals the whole time. She takes the calls. She reviews the deck. She agrees to the next panel. Everything about the relationship reads as validated.
Meanwhile the actual recommendation rate inside her own clinic sits at zero, and nobody's tracking that number closely enough to notice. It surfaces two quarters later as a pilot that never expands past the first site, a KOL relationship that never turns into usage data, or a fundraising story that leans on a name instead of a number.
By the time it's visible, it looks like a sales problem. It was never a sales problem. It was a content problem, from the start, aimed at the wrong version of trust.
What actually closes it
You can't argue a clinician into the private yes. But you can write content, and build a product experience, that answers the private question instead of the public one. That's what changes what she's willing to say to her own patients.
Four things make the difference.
Name the failure mode. If the tool doesn't work well for a specific patient type, say so, and say what you'd recommend instead. A clinician trusts a company that tells her where something stops working more than one that claims it works for everyone. Silence on limitations reads as either naivety or evasion, and she has no way to tell which.
Show the 90 second version. If the product needs a five minute walkthrough to make sense to a first time patient, it won't get recommended inside a real visit, no matter how good it is. That's a content problem and a product problem at once: the explanation has to compress to the time she actually has, not the time a demo gives it.
Use a real patient in the example. A clinician deciding whether to recommend something to her own patient wants a comparable patient. A specific age range, a specific condition, what changed and over what timeframe: that reads as evidence. A generic success story reads as an ad, and she's spent a career learning to discount ads.
Answer the accountability question before she asks it. State plainly what happens if a patient has a bad experience: who gets contacted, and what the escalation path looks like. A clinician who has to ask this out loud has usually already decided not to recommend the product yet. Answer it in writing, on the page, before the question forms.
It shows up everywhere a clinician can be cheaply generous
Advisory boards aren't the only place this pattern hides. A clinician commenting supportively on your LinkedIn post costs her nothing. Attending your webinar costs her nothing. Agreeing to a 30 minute call with a founder she finds interesting costs her nothing.
Watch for the moment the ask changes from her time to her name attached to a real outcome. That's where the cheap yes and the expensive yes split apart, and it's the only place worth measuring.
Real signal looks different, and it's usually smaller and less visible than a testimonial. A clinician who quietly adds your tool to her own referral pathway. One who brings it up unprompted to a colleague at a conference, without you in the room to hear it. One who asks a hard, specific, slightly annoyed question, because she's actually trying to use the thing with a real patient next Tuesday and something isn't working the way the demo suggested.
That irritation is worth more than a dozen warm quotes. Nobody gets specifically annoyed about a product they haven't actually tried to use.
What this means for the fundraising story
An investor's diligence process eventually runs the same check you should be running yourself. A named advisory board is only a starting point. The sharper question, and the one a good diligence associate asks directly, is how many of those advisors have put the product in front of their own patients, and what happened when they did.
A founder who can answer that with a real number, even a small one, is showing something a logo can't: that the clinical relationships are load-bearing. A founder who can only point to quotes and panel appearances is showing something else entirely, whether or not that's the intent.
Keep building the advisory board. Just track a second number alongside it, and be honest with yourself about which one the fundraising deck is actually leaning on.
A test you can run this week
Pull up whatever your best clinical advisor has said publicly about the product: the webinar clip, the quote, the panel appearance, the LinkedIn comment. Then ask her directly, privately, how many of her own patients she's personally recommended it to.
If the gap between those two numbers is wide, your content and your product conversations have been built for the yes that costs her nothing. That's not wasted work. It's just aimed at the wrong buyer inside the same person.
The fix is a shift in what you're asking your content to do: stop writing to earn the endorsement, and start writing to survive the exam room.
What your sales team should stop leading with
Most digital health sales decks open with the advisory board slide. It's an easy slide to build and it photographs well. But leading with it trains the room to evaluate you on the cheap yes, and then wonder later why the pilot stalls once the actual clinicians on staff get involved.
Lead with the 90 second explanation instead. Show the specific patient it works for and the one it doesn't, out loud, before anyone asks. Put the accountability answer on the page, not in a follow-up email three weeks after the question comes up in a meeting.
A room full of clinicians can tell the difference between a company presenting for their approval and one that's already done the work of thinking through what happens when a real patient uses this on a bad day. Only one of those gets recommended.
The number that actually matters
An advisory board logo is easy to get and easy to put in front of an investor. A real recommendation rate inside a working clinic is harder to get, and worth more, to the clinician and to the diligence associate who eventually asks how you know your clinical champions actually use the thing.
Content built for the version of trust that costs a clinician nothing will keep collecting board seats and quotes. Content built for the version that costs her something, her judgment and her relationship with a real patient, will start collecting a number worth showing.
How many of her patients are actually using it. That's the only advisory board metric that predicts anything.